Mersana Therapeutics Inc (FRA:0M4)
€ 3.087 -0.127 (-3.95%) Market Cap: 387.00 Mil Enterprise Value: 223.79 Mil PE Ratio: 0 PB Ratio: 11.06 GF Score: 37/100

Mersana Therapeutics Inc at Stifel Healthcare Conference (Virtual) Transcript

Nov 17, 2021 / 08:20PM GMT
Release Date Price: €7.8
Alex Thompson
Stifel Financial Corp. - Analyst

Great. Good afternoon, everyone. My name is Alex Thompson; I'm an associate here on the biotech team at Stifel. It's my pleasure to introduce Anna Protopapas, President and CEO of Mersana Therapeutics. I'm going to throw it over to her to walk through an overview of the Company. Over to you, Anna.

Anna Protopapas
Mersana Therapeutics, Inc. - President and CEO

Thank you, Alex, and thank you for having us here today.

Moving on to slide 2. Before I start, I just want to remind you that in this presentation, I will be making forward-looking statements. At Mersana, we aspire to ADC leadership by innovating to capture the full potential of this important therapeutic modality and ultimately make a real difference in patients. ADCs are a proven therapeutic modality. We have 11 on the market and over 100 in clinical development, but there is significant opportunity for ADCs to play an even bigger role in cancer treatment, and we want to be on the leading edge of this innovation.

With Dolaflexin,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot